GPER Mediates a Feedforward FGF2/FGFR1 Paracrine Activation Coupling CAFs to Cancer Cells toward Breast Tumor Progression.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
07 03 2019
Historique:
received: 18 02 2019
revised: 01 03 2019
accepted: 04 03 2019
entrez: 15 3 2019
pubmed: 15 3 2019
medline: 15 3 2019
Statut: epublish

Résumé

The FGF2/FGFR1 paracrine loop is involved in the cross-talk between breast cancer cells and components of the tumor stroma as cancer-associated fibroblasts (CAFs). By quantitative PCR (qPCR), western blot, immunofluorescence analysis, ELISA and ChIP assays, we demonstrated that 17β-estradiol (E2) and the G protein estrogen receptor (GPER) agonist G-1 induce the up-regulation and secretion of FGF2 via GPER together with the EGFR/ERK/c-fos/AP-1 signaling cascade in (ER)-negative primary CAFs. Evaluating the genetic alterations from METABRIC and TCGA datasets, we then assessed that FGFR1 is the most frequently amplified FGFRs family member and its amplification/expression associates with shorter survival rates in breast cancer patients. Therefore, in order to assess the functional FGF2/FGFR1 interplay between CAFs and breast cancer cells, we generated the FGFR1-knockout MDA-MB-231 cells using CRISPR/Cas9 genome editing strategy. Using conditioned medium from estrogen-stimulated CAFs, we established that the activation of FGF2/FGFR1 paracrine signaling triggers the expression of the connective tissue growth factor (CTGF), leading to the migration and invasion of MDA-MB-231 cells. Our findings shed new light on the role elicited by estrogens through GPER in the activation of the FGF2/FGFR1 signaling. Moreover, our findings may identify further biological targets that could be considered in innovative combination strategies halting breast cancer progression.

Identifiants

pubmed: 30866584
pii: cells8030223
doi: 10.3390/cells8030223
pmc: PMC6468560
pii:
doi:

Substances chimiques

1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone 0
Culture Media, Conditioned 0
Cyclopentanes 0
GPER1 protein, human 0
Proto-Oncogene Proteins c-fos 0
Quinolines 0
Receptors, Estrogen 0
Receptors, G-Protein-Coupled 0
Fibroblast Growth Factor 2 103107-01-3
Connective Tissue Growth Factor 139568-91-5
Estradiol 4TI98Z838E
FGFR1 protein, human EC 2.7.10.1
Receptor, Fibroblast Growth Factor, Type 1 EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Oncogene. 2018 Sep;37(39):5340-5354
pubmed: 29858603
Nat Commun. 2016 May 10;7:11479
pubmed: 27161491
J Cell Physiol. 2009 Jul;220(1):189-95
pubmed: 19277979
Nat Rev Cancer. 2016 Aug 23;16(9):582-98
pubmed: 27550820
Exp Cell Res. 2003 Jul 1;287(1):190-8
pubmed: 12799194
Mol Cell Endocrinol. 2009 Sep 24;308(1-2):32-8
pubmed: 19464786
Neuroscience. 2016 Apr 5;319:9-22
pubmed: 26804240
Nature. 2001 May 17;411(6835):375-9
pubmed: 11357145
Clin Cancer Res. 2011 Aug 15;17(16):5275-86
pubmed: 21712446
Breast Cancer Res. 2012 Jan 17;14(1):R12
pubmed: 22251451
Tumour Biol. 2015 Mar;36(3):1385-94
pubmed: 25680413
Nat Rev Cancer. 2017 May;17(5):318-332
pubmed: 28303906
Cell Rep. 2016 Mar 15;14(10):2490-501
pubmed: 26947069
Cell. 2005 May 6;121(3):335-48
pubmed: 15882617
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21737-42
pubmed: 21098263
Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1492-5
pubmed: 12433733
Nat Rev Drug Discov. 2011 Jan;10(1):47-60
pubmed: 21193867
Cancer. 2015 Jan 1;121(1):8-16
pubmed: 25043972
Semin Cell Dev Biol. 2016 May;53:126-35
pubmed: 26463732
EMBO Mol Med. 2014 Apr;6(4):467-81
pubmed: 24503018
Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8713-7
pubmed: 18552176
Int J Cancer. 2008 Nov 15;123(10):2229-38
pubmed: 18777559
Clin Cancer Res. 2014 Jun 15;20(12):3299-309
pubmed: 24771645
Cancer Discov. 2013 Mar;3(3):264-79
pubmed: 23418312
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
J Endocrinol. 2010 Feb;204(2):105-14
pubmed: 19767412
Mol Cancer Res. 2012 Aug;10(8):995-1009
pubmed: 22714124
J Cell Sci. 2007 Jun 15;120(Pt 12):2053-65
pubmed: 17550972
Mol Cancer. 2018 Jan 11;17(1):5
pubmed: 29325547
Cells. 2018 Jul 15;7(7):
pubmed: 30011957
Cancer Cell. 2012 Mar 20;21(3):309-22
pubmed: 22439926
Mol Cancer. 2011 Feb 22;10:22
pubmed: 21342498
Trends Cell Biol. 2015 Apr;25(4):221-33
pubmed: 25467007
Nat Med. 2003 Aug;9(8):999-1000
pubmed: 12894162
Nature. 2004 Nov 18;432(7015):332-7
pubmed: 15549095
Oncotarget. 2017 Apr 11;8(15):24063-24076
pubmed: 28445992
Cancer Cell. 2007 Dec;12(6):559-71
pubmed: 18068632
Clin Cancer Res. 2015 Jun 15;21(12):2684-94
pubmed: 26078430
Endocr J. 2009;56(1):1-7
pubmed: 18497452
Cancer Res. 2001 Nov 15;61(22):8135-42
pubmed: 11719442
Expert Opin Ther Targets. 2015;19(10):1361-77
pubmed: 26125971
FEBS Lett. 2012 Dec 14;586(24):4270-5
pubmed: 23142580
Mol Cancer Ther. 2012 Oct;11(10):2301-5
pubmed: 22879364
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
Cell Signal. 2014 Jul;26(7):1466-75
pubmed: 24662263
Breast Cancer Res. 2018 Aug 15;20(1):97
pubmed: 30111373
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Sci Rep. 2016 Apr 13;6:24354
pubmed: 27072893
Sci Rep. 2017 Aug 17;7(1):8509
pubmed: 28819120
EMBO J. 2009 Mar 4;28(5):523-32
pubmed: 19153601
Cells. 2014 Jun 10;3(2):563-91
pubmed: 24918976
Mol Carcinog. 2017 Feb;56(2):580-593
pubmed: 27341075
Cell Death Dis. 2015 Jul 30;6:e1834
pubmed: 26225773
Breast Cancer Res. 2013;15(4):R64
pubmed: 23947803
Nat Rev Cancer. 2013 Feb;13(2):97-110
pubmed: 23344542
J Cell Biol. 2008 Nov 3;183(3):543-54
pubmed: 18955554
Oncogene. 2013 Feb 7;32(6):678-88
pubmed: 22430216
EMBO J. 1998 Oct 15;17(20):5896-904
pubmed: 9774334
Mol Cancer Res. 2012 Nov;10(11):1403-18
pubmed: 23024188
Cancer Res. 2014 Aug 1;74(15):4053-64
pubmed: 24894716
Cancer Cell. 2003 Jun;3(6):537-49
pubmed: 12842083
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Int J Mol Med. 2016 Jul;38(1):3-15
pubmed: 27245147
Gene. 2001 Jun 27;271(2):171-82
pubmed: 11418238
Cancer Res. 2000 Dec 15;60(24):7163-9
pubmed: 11156426
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
Biofactors. 2009 Mar-Apr;35(2):200-8
pubmed: 19449449
Cells. 2018 Dec 08;7(12):
pubmed: 30544798
Mol Cancer Ther. 2016 Sep;15(9):2096-106
pubmed: 27371729
Cells. 2018 Oct 05;7(10):
pubmed: 30301152
J Pathol. 2003 Jul;200(4):429-47
pubmed: 12845611
Curr Cancer Drug Targets. 2012 Jun;12(5):531-42
pubmed: 22414008
Cells. 2018 Nov 09;7(11):
pubmed: 30423928
Biochim Biophys Acta. 2013 Jul;1832(7):1070-8
pubmed: 23123598
Best Pract Res Clin Endocrinol Metab. 2015 Aug;29(4):557-68
pubmed: 26303083
Front Oncol. 2014 Mar 27;4:62
pubmed: 24734219
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925

Auteurs

Maria Francesca Santolla (MF)

Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy. mariafrancesca.santolla@unical.it.

Adele Vivacqua (A)

Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy. adele.vivacqua@unical.it.

Rosamaria Lappano (R)

Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy. rosamaria.lappano@unical.it.

Damiano Cosimo Rigiracciolo (DC)

Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy. damianorigiracciolo@yahoo.it.

Francesca Cirillo (F)

Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy. francesca.cirillo@unical.it.

Giulia Raffaella Galli (GR)

Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy. giulia.r.galli@gmail.com.

Marianna Talia (M)

Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy. mariannatalia11@gmail.com.

Giuseppe Brunetti (G)

University of Natural Resources and Life Sciences, 1180 Vienna, Austria. giusep.bru@gmail.com.

Anna Maria Miglietta (AM)

Regional Hospital, 87100 Cosenza, Italy. annamariamiglietta@virgilio.it.

Antonino Belfiore (A)

Endocrinology, Department of Clinical and Experimental Medicine, University of Catania, Garibaldi-Nesima Hospital, 95122 Catania, Italy. antonino.belfiore@unict.it.

Marcello Maggiolini (M)

Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy. marcellomaggiolini@yahoo.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH